Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV randomized double-blind trial of seasonal influenza vaccination in at-risk children aged 12 to 35 months
2019-001186-33Phase 4Active
- Sponsor
- Foundation for the Incentive of Research
- Start
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Fluarix Quadrivalent in influenza and acute respiratory illness (ARI) (2 arms), sponsored by Foundation for the Incentive of Research. Primary endpoints: Efficacy against episodes of acute respiratory infection, Severity of acute respiratory infection and 2 more. Started Jun 2019; status: active.
02
Drugs
Fluarix Quadrivalent
03
Conditions
influenzaacute respiratory illness (ARI)
Beyond the preview
Go deeper on 2019-001186-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001186-33.